In the first edition of the interview series, we spoke with FogPharma’s Chief Scientific Officer, Howard Stern.

As a leading figure in drugging the “undruggable”, Howard shares some fascinating insights into how FogPharma is unlocking new drug targets and gives his take on this area of R&D.

Topics covered include:

  • How are you working to overcome the major limiting factors of using Helicon™ peptides?

  • Outside of your area of focus, what areas of “undruggable” research are you most excited about?

  • What conversations need to happen to advance the “undruggable” industry?


Access your Exclusive Copy of Howard’s Interview here